Heart monitoring strategies for older adults receiving cancer treatment
Compares intensive heart monitoring with usual care in adults aged 65 or older with cancer.
Plain-language title generated from the registry record
Registry title: Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
Key facts
- Where
- Barcelona, Córdoba, Galdakao, Madrid, Málaga, Salamanca, Santiago de Compostela, Seville, and Valladolid, SpainSee the 14 sites
Where in Spain
- Hospital Universitario Vall d'HebronBarcelona, SpainNot yet recruiting
- Hospital Universitario Reina SofiaCórdoba, SpainNot yet recruiting
- Hospital de Galdakao-UsansoloGaldakao, SpainNot yet recruiting
- Hospital G. Universitario Gregorio MarañónMadrid, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Hospital Universitario de la PrincesaMadrid, SpainNot yet recruiting
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainNot yet recruiting
- Hospital Universitario Puerta de HierroMadrid, SpainNot yet recruiting
- Hospital Universitario Ramón y CajalMadrid, SpainNot yet recruiting
- Hospital Universitario Virgen de la VictoriaMálaga, SpainNot yet recruiting
- Complejo Asistencial Universitario de SalamancaSalamanca, SpainTaking people
- Hospital Clínico Universitario de Santiago de CompostelaSantiago de Compostela, SpainNot yet recruiting
- Hospital Universitario Virgen del RocioSeville, SpainNot yet recruiting
- Hospital Universitario Rio HortegaValladolid, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
- Trial code
- NCT03711110
- Record updated
- 21 March 2025
- Original description
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care) vs. secondary (current clinical practice where intensive cardiovascular monitoring is not routinely performed and cardiotoxicity patient care is based on the onco-hematologist criteria).Read full original descriptionShow less
Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care) vs. secondary (current clinical practice where intensive cardiovascular monitoring is not routinely performed and cardiotoxicity patient care is based on the onco-hematologist criteria).
The primary endpoint is to determine whether this primary prevention englobing cardiovascular monitoring plus intensive multidisciplinary management is superior to the current clinical practice in reducing all cause mortality.
Other secondary objectives of the study are to analyze the impact of this intensive cardiovascular monitoring strategy on the incidence of cardiovascular mortality, oncological mortality, hospitalization and/or urgent care due to cardiovascular complications, hospitalization and/or urgent oncological care due to cancer complications, tumor progression and cost-effectiveness analysis.
A total of 514 patients ≥ 65 years old diagnosed with any of the following onco-hematological cancers, colon, breast, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia or myeloma, undergoing standardized anti-tumoral treatment, will be recruited.
The incidence of primary and secondary outcomes will be measured at 2 and 5 years
Inclusion: > 65 years old; Expected survival >1 year; Colon cancer, breast cancer, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia, myeloma; Signature on the informed consent.
Exclusion: Patients who had received previous potentially cardiotoxic anticancer treatment; Patients included in clinical trials will be excluded if they interfere with the CARTIER follow-up protocol. If they do not interfere they can be included.